title: Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
abstract: To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P<0.002) with a poorer performance status (26% vs. 17%, P<0.002) than DLBCL patients. The complete response rate among PTCL patients was significantly lower than among DLBCL patients (39% vs. 67%, P<0.008), as was the 3-year overall survival rate (26% vs. 50%, P=0.005), and Cox multivariate analysis revealed immunophenotype, performance status, and extranodal site involved to be significantly associated with shorter overall survival (P=0.045, P=0.007, and P=0.034, respectively). Our findings suggest that PTCL patients tend to have a poor prognosis associated with several initial risk factors. Moreover, the T-cell phenotype itself appears to have a significant impact on overall survival. Thus, standard CHOP chemotherapy may be inadequate for PTCLs, especially in patients with high-risk factors. The development of newly stratified therapies for the treatment of PTCLs would be highly desirable.
authors.affiliation: Department of Hematology, Aomori Prefectural Hospital, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Akagi
authors.forename: Naoto
authors.initials: N
authors.lastname: Takahashi
authors.forename: Kouhei
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ishizawa
authors.forename: Kazunori
authors.initials: K
authors.lastname: Murai
authors.forename: Katsushi
authors.initials: K
authors.lastname: Tajima
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Ikeda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kameoka
authors.forename: Junnichi
authors.initials: J
authors.lastname: Kameoka
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ito
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kato
authors.forename: Hideyoshi
authors.initials: H
authors.lastname: Noji
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Shichishima
authors.forename: Jugoh
authors.initials: J
authors.lastname: Itoh
authors.forename: Ryo
authors.initials: R
authors.lastname: Ichinohasama
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
authors.forename: Yoji
authors.initials: Y
authors.lastname: Ishida
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sawada
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone